Lexaria Bioscience Receives Groundbreaking U.S. Patent Allowance for its DehydraTECHTM Delivery of THC, NSAIDs, and Nicotine ...
November 01 2017 - 9:32AM
InvestorsHub NewsWire
Lexaria Bioscience Receives Groundbreaking U.S. Patent Allowance
for its DehydraTECHTM Delivery of THC, NSAIDs, Nicotine and
Vitamins.
Kelowna, British Columbia –-
October 31, 2017 –- InvestorsHub NewsWire -- Lexaria Bioscience
Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or
“Lexaria”) a drug delivery platform innovator, announces it has
received a new Notice of Allowance from the United States Patent
and Trademark Office (“USPTO”) for the use of its technology as a
delivery platform for all cannabinoids including THC; fat soluble
vitamins; non steroidal anti-inflammatory pain medications
(“NSAIDs”); and nicotine.
This Notice of Allowance applies to the delivery of all active
pharmacological ingredients (“APIs”) Lexaria had been seeking.
While Lexaria has always had confidence in its patent
applications, the rapid allowance for this broad API applicability
is significantly ahead of Company expectations. As was true with
the Company’s existing non-psychoactive cannabinoid patent that was
granted in 2016, Lexaria expects formal patent issuance within
three to four months which is expected to provide protection until
at least 2035.
Under USPTO practice, there is no opposition period between
allowance and issuance. The patent application number is
15/225,799, “Food and Beverage Compositions Infused With Lipophilic
Active Agents and Methods of Use Thereof”.
Lexaria also continues to advance all its additional patent
applications in various countries as it levers patent success in
the USA. For example, one of the Company’s patent applications has
recently entered the active patent investigation phase in
China.
“Issuance of this broad patent will give Lexaria the ability to
ramp up our technology outlicensing activities especially within
the pharmaceutical sector where the expanded API capacity of our
DehydraTECHTM delivery platform will be most applicable,” said John
Docherty, President.
“This wide-ranging patent allowance from the USPTO exceeds our
expectations” said Chief Executive Officer Chris Bunka. “This
vastly expanded intellectual property protection will enable us to
aggressively pursue new business opportunities in 2018 such as what
could be the world’s first nicotine edibles for the smokeless
tobacco industry, or enhanced products for NSAIDderived pain
management, as well as in the rapidly growing cannabis market.”
Lexaria’s patented DehydraTECH™ technology is focused on improved
delivery methodologies of many commonly used API substances. As
such, it provides an additional layer of effectiveness that is
designed to harmonize with the intellectual property of third
parties. generic API substances can utilize Lexaria’s pate to
partner with the world’s leading firms as they deliver best large
consumer groups.
Lexaria is presently investigating and will continue to pursue
additional technolog deliver value to its growing portfolio of
patented technologies.
About Lexaria Lexaria Bioscience Corp. has developed and out
promotes healthier ingestion methods, lower overall dosing and
lipophilic active molecules. Lexaria has mult the world and was
granted its first patent cannabinoids. Lexaria’s technology
delivery to the bloodstream; and important taste bioactive
molecules including cannabinoids, vitamins, (NSAIDs),
nicotine and other molecules. www.lexariabioscience.com
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(778) 796-1897
Or
NetworkNewsWire (NNW)
www.NetworkNewsWire.com
FORWARD-LOOKING STATEMENTS
This release includes
forward-looking statements. Statements which are not historical
facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future
financial position, results of operations, cash flows, financing
plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management
for future operations, including statements that include words such
as "anticipate," "if," "believe," "plan," "estimate," "expect,"
"intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not
limited to: that any additional patent protection will be realized
or that patent achievements will deliver material results. Such
forward-looking statements are estimates reflecting the Company's
best judgment based upon current information and involve a number
of risks and uncertainties, and there can be no assurance that
other factors will not affect the accuracy of such forward-looking
statements. Factors which could cause actual results to differ
materially from those estimated by the Company include, but are not
limited to, government regulation, managing and maintaining growth,
the effect of adverse publicity, litigation, competition,
scientific discovery, the patent application and approval process
and other factors which may be identified from time to time in the
Company's public announcements and filings. There is no assurance
that existing capital is sufficient for the Company's needs or that
it will be able to raise additional capital. There is no assurance
the Company will be capable of developing, marketing, licensing, or
selling edible products containing nicotine or any other active
ingredient. There is no assurance that any planned corporate
activity, scientific research or study, business venture,
technology licensing pursuit, patent application or allowance,
consumer study, or any initiative will be pursued, or if pursued,
will be successful. There is no assurance that any of Lexaria’s
postulated uses, benefits, or advantages for the patented and
patent-pending technology will in fact be realized in any manner or
in any part. No statement herein has been evaluated by the Food and
Drug Administration (FDA). Lexaria-associated products are
not intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release
Lexaria Bioscience (CSE:LXX)
Historical Stock Chart
From May 2024 to Jun 2024
Lexaria Bioscience (CSE:LXX)
Historical Stock Chart
From Jun 2023 to Jun 2024